X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs SANOFI INDIA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB SANOFI INDIA DR. REDDYS LAB/
SANOFI INDIA
 
P/E (TTM) x 30.5 34.3 88.9% View Chart
P/BV x 3.0 6.5 45.7% View Chart
Dividend Yield % 0.9 1.4 65.5%  

Financials

 DR. REDDYS LAB   SANOFI INDIA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
SANOFI INDIA
Dec-16
DR. REDDYS LAB/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3,3974,560 74.5%   
Low Rs2,5604,400 58.2%   
Sales per share (Unadj.) Rs856.51,028.5 83.3%  
Earnings per share (Unadj.) Rs78.0129.0 60.5%  
Cash flow per share (Unadj.) Rs139.9186.0 75.2%  
Dividends per share (Unadj.) Rs20.0068.00 29.4%  
Dividend yield (eoy) %0.71.5 44.2%  
Book value per share (Unadj.) Rs739.8753.6 98.2%  
Shares outstanding (eoy) m165.7423.03 719.7%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.54.4 79.8%   
Avg P/E ratio x38.234.7 110.0%  
P/CF ratio (eoy) x21.324.1 88.4%  
Price / Book Value ratio x4.05.9 67.7%  
Dividend payout %25.752.7 48.7%   
Avg Mkt Cap Rs m493,632103,174 478.4%   
No. of employees `00022.73.6 626.0%   
Total wages/salary Rs m31,0683,592 864.9%   
Avg. sales/employee Rs Th6,259.06,537.7 95.7%   
Avg. wages/employee Rs Th1,369.8991.4 138.2%   
Avg. net profit/employee Rs Th569.7819.8 69.5%   
INCOME DATA
Net Sales Rs m141,96123,686 599.3%  
Other income Rs m1,715708 242.2%   
Total revenues Rs m143,67624,394 589.0%   
Gross profit Rs m24,7225,281 468.1%  
Depreciation Rs m10,2661,313 781.9%   
Interest Rs m63415 4,226.7%   
Profit before tax Rs m15,5374,661 333.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9651,691 175.3%   
Profit after tax Rs m12,9212,970 435.1%  
Gross profit margin %17.422.3 78.1%  
Effective tax rate %19.136.3 52.6%   
Net profit margin %9.112.5 72.6%  
BALANCE SHEET DATA
Current assets Rs m96,83715,673 617.9%   
Current liabilities Rs m84,1996,678 1,260.8%   
Net working cap to sales %8.938.0 23.4%  
Current ratio x1.22.3 49.0%  
Inventory Days Days7376 96.5%  
Debtors Days Days9822 437.7%  
Net fixed assets Rs m102,5528,098 1,266.4%   
Share capital Rs m829230 360.0%   
"Free" reserves Rs m121,79217,088 712.7%   
Net worth Rs m122,62117,356 706.5%   
Long term debt Rs m5,4490-   
Total assets Rs m218,16525,400 858.9%  
Interest coverage x25.5311.7 8.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.9 69.8%   
Return on assets %6.211.8 52.9%  
Return on equity %10.517.1 61.6%  
Return on capital %12.926.9 47.9%  
Exports to sales %54.624.5 223.0%   
Imports to sales %9.428.0 33.4%   
Exports (fob) Rs m77,5205,801 1,336.3%   
Imports (cif) Rs m13,2746,627 200.3%   
Fx inflow Rs m81,6707,145 1,143.0%   
Fx outflow Rs m26,3556,846 385.0%   
Net fx Rs m55,315299 18,500.0%   
CASH FLOW
From Operations Rs m21,4443,226 664.7%  
From Investments Rs m-18,404-1,555 1,183.5%  
From Financial Activity Rs m-3,692-1,818 203.1%  
Net Cashflow Rs m-1,144-147 778.2%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 5.4 14.4 37.5%  
FIIs % 35.3 14.6 241.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 15,184 499.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   MERCK LTD  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 16, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - WOCKHARDT LTD. COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS